Coya and ARScience expand global licensing agreement for COYA 301
Under the terms of the agreement, Coya obtained the rights for the development and commercialisation of its product COYA 301 as a single agent to treat several autoimmune
The partnership will combine the research capabilities of Dr Emyr Lloyd-Evans & Dr Helen Waller-Evans in lysosomal biology, MDI’s drug discovery capabilities and the fragment-based drug discovery platform
AB-101 is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use along with monoclonal antibodies or innate-cell engagers in the out-patient environment. Artiva